Brief: Cutia Therapeutics Says CU-40104 Obtains Clinical Trial Approval From NMPA, China
16/03/2026 01:43
March 16 (Reuters) - Cutia Therapeutics 2487.HK: CU-40104 OBTAINS CLINICAL TRIAL APPROVAL FROM NMPA, CHINA Further company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cutia Therapeutics
See all newsBrief: Cutia Therapeutics To Implement Share Repurchase Program From Oct 2 To Dec 31
Brief: Cutia Therapeutics Says Cu-40102 Bags Marketing Approval From Macao Pharmaceutical Administration Bureau
Brief: Cutia Therapeutics Says Nmpa Accepts Biologics License Application For Cu-20101
Brief: Cutia Therapeutics Posts HY Loss Of RMB180.4 MLN
Brief: Cutia Therapeutics Says CU-30101 Obtains Drug Marketing Authorization By NMPA China